A PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Papayannidis C., DiNardo C., Montesinos P., Schuh A., Vyas P., Wei A., Ommen H., Semochkin S., Kim H., Larson R., Koprivnikar J., Frankfurt O., Thol F., Chromik J., Byrne J., Pigneux A., Thomas X., Salamero O., Vidriales M., Doronin V., Dohner H., Fathi A., Laille E., Yu X., Hasan M., Martin-Regueira P., de Botton S.

Type

Conference paper

Publication Date

10/2021

Volume

106

Pages

1 - 1

Permalink